Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

NCT00431340 is registered in ClinicalTrials.gov with Valerio Therapeutics as lead sponsor.

NCT NCT00431340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00431340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Lead sponsor
Valerio Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2007
Completion date
June 30, 2007
Enrollment
4 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma